{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:00:05Z","timestamp":1774407605747,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005049","name":"Science and Engineering Research Council","doi-asserted-by":"publisher","award":["CRG\/2022\/004698"],"award-info":[{"award-number":["CRG\/2022\/004698"]}],"id":[{"id":"10.13039\/501100005049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117705","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:24:27Z","timestamp":1746530667000},"page":"117705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and development of chromene-3-carboxylate derivatives as antidiabetic agents: Exploring the antidiabetic potential via dual inhibition of angiotensin II type 1 receptor and neprilysin enzyme"],"prefix":"10.1016","volume":"293","author":[{"given":"Shikha","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav S.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayant","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-5258","authenticated-orcid":false,"given":"Hemant R.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10394","key":"10.1016\/j.ejmech.2025.117705_bib3","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/S0140-6736(23)00223-4","article-title":"Type 1 diabetes","volume":"401","author":"Quattrin","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib4","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202203150","article-title":"Type 1 diabetes mellitus","volume":"175","author":"Syed","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117705_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4239\/wjd.v6.i6.850","article-title":"Diabetes mellitus: the epidemic of the century","volume":"6","author":"Kharroubi","year":"2015","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"Journal of epidemiology and global health"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117705_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/kjm2.12800","article-title":"Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies","volume":"40","author":"Chong","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117705_bib9","first-page":"452","article-title":"New and emerging drugs and targets for type 2 diabetes: reviewing the evidence","volume":"7","author":"Miller","year":"2014","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.ejmech.2025.117705_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.117705_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110708","article-title":"Type II diabetes mellitus: a review on recent drug based therapeutics","volume":"131","author":"Padhi","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117705_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00125-023-06069-1","article-title":"Remission of type 2 diabetes: always more questions, but enough answers for action","volume":"67","author":"Rothberg","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117705_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.46747\/cfp.7005310","article-title":"Shared decision-making approach to type 2 diabetes management","volume":"70","author":"MacDonald","year":"2024","journal-title":"Can. Fam. Physician"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117705_bib14","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","article-title":"Molecular and cellular mechanisms of cardiovascular disorders in diabetes","volume":"118","author":"Shah","year":"2016","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00125-022-05857-5","article-title":"Cardiovascular outcomes in type 1 and type 2 diabetes","volume":"66","author":"Rosengren","year":"2023","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117705_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2796.1997.tb00006.x","article-title":"Diabetes as a risk factor for myocardial infarction: population and gender perspectives","volume":"241","author":"Lundberg","year":"1997","journal-title":"J. Intern. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117705_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2025.117705_bib18","article-title":"Comprehensive management of type 2 diabetes mellitus: from prevention to novel therapeutic approaches","volume":"2","author":"Karunarathna","year":"2024","journal-title":"Uva Clinical Lab. Retrieved from Comprehensive Management of Type"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17446651.2023.2204941","article-title":"Treatment of type 2 diabetes patients with heart conditions","volume":"18","author":"Aktas","year":"2023","journal-title":"Expet Rev. Endocrinol. Metabol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117705_bib20","doi-asserted-by":"crossref","first-page":"8994","DOI":"10.3390\/ijms22168994","article-title":"Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias","volume":"22","author":"Sutanto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117705_bib21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4239\/wjd.v15.i5.867","article-title":"Role of angiotensin receptor-neprilysin inhibitor in diabetic complications","volume":"15","author":"Liu","year":"2024","journal-title":"World J. Diabetes"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117705_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1358863X12450094","article-title":"Link between the renin\u2013angiotensin system and insulin resistance: implications for cardiovascular disease","volume":"17","author":"Zhou","year":"2012","journal-title":"Vasc. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117705_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010070","article-title":"Angiotensin II inhibits insulin-stimulated GLUT4 translocation and akt activation through tyrosine nitration-dependent mechanisms","volume":"5","author":"Csibi","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117705_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/1753-0407.13389","article-title":"Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: controversial points and a promising arena","volume":"15","author":"AlAnazi","year":"2023","journal-title":"J. Diabetes"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117705_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"D\u00edez","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40119-023-00323-8","article-title":"Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists","volume":"12","author":"Dalal","year":"2023","journal-title":"Cardiology and Therapy"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117705_bib27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00125-019-4889-y","article-title":"Neprilysin inhibition: a new therapeutic option for type 2 diabetes?","volume":"62","author":"Esser","year":"2019","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117705_bib28","first-page":"73","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"Heart Fail."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117705_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ihj.2022.04.003","article-title":"Safety and efficacy of ARNI (Valsartan\/Sacubitril) vs ACEI (Enalapril) in acute heart failure\u2013A prospective observational study","volume":"74","author":"Bhat","year":"2022","journal-title":"Indian Heart J."},{"key":"10.1016\/j.ejmech.2025.117705_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117705_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin\u2010receptor neprilysin inhibitor on cardiac reverse remodeling: meta\u2010analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"98","key":"10.1016\/j.ejmech.2025.117705_bib32","doi-asserted-by":"crossref","first-page":"13556","DOI":"10.1039\/D2CC04825F","article-title":"Myofibroblast specific targeting approaches to improve fibrosis treatment","volume":"58","author":"Beaven","year":"2022","journal-title":"Chem. Commun."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117705_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028729","article-title":"Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients","volume":"101","author":"Ye","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.ejmech.2025.117705_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.137462","article-title":"Solvent-free synthesis, biological evaluation and in silico studies of novel 2-amino-7-(bis (2-hydroxyethyl) amino)-4H-chromene-3-carbonitrile derivatives as potential a-amylase inhibitors","volume":"1301","author":"Chothani","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117705_bib35","doi-asserted-by":"crossref","first-page":"15691","DOI":"10.1039\/D4RA02143F","article-title":"Innovation of 6-sulfonamide-2 H-chromene derivatives as antidiabetic agents targeting \u03b1-amylase, \u03b1-glycosidase, and PPAR-\u03b3 inhibitors with in silico molecular docking simulation","volume":"14","author":"Thabet","year":"2024","journal-title":"RSC advances"},{"key":"10.1016\/j.ejmech.2025.117705_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108097","article-title":"Discovery of novel 6-(piperidin-1-ylsulfonyl)-2H-chromenes targeting \u03b1-glucosidase, \u03b1-amylase, and PPAR-\u03b3: design, synthesis, virtual screening, and anti-diabetic activity for type 2 diabetes mellitus","volume":"111","author":"Thabet","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117705_bib37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s10593-015-1779-1","article-title":"Synthesis, characterization, and antibacterial evaluation of new alkyl 2-amino-4-aryl-4 H-chromene-3-carboxylates","volume":"51","author":"Gholipour","year":"2015","journal-title":"Chem. Heterocycl. Compd."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bmcl.2018.10.018","article-title":"Synthesis, in vitro and in vivo evaluation of 2-aryl-4H-chromene and 3-aryl-1H-benzo [f] chromene derivatives as novel \u03b1-glucosidase inhibitors","volume":"29","author":"Spasov","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117705_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.saa.2018.07.009","article-title":"Synthesis, characterization, anti-diabetic potential and DFT studies of 7-hydroxy-4-methyl-2-oxo-2H-chromene-8-carbaldehyde oxime","volume":"205","author":"Ghazvini","year":"2018","journal-title":"Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"},{"issue":"21","key":"10.1016\/j.ejmech.2025.117705_bib40","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.2174\/1389557522666220331161636","article-title":"Chromenes-a novel class of heterocyclic compounds: recent advancements and future directions","volume":"22","author":"Chaudhary","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117705_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110019","article-title":"A structure-based pharmacophore modelling approach to identify and design new neprilysin (NEP) inhibitors: an in silico-based investigation","volume":"756","author":"Thakur","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib42","doi-asserted-by":"crossref","first-page":"217S","DOI":"10.1093\/ajcn\/87.1.217S","article-title":"Glucose metabolism and hyperglycemia","volume":"87","author":"Giugliano","year":"2008","journal-title":"The American journal of clinical nutrition"},{"key":"10.1016\/j.ejmech.2025.117705_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117705_bib44","first-page":"28","article-title":"Hyperglycemia induction in HepG2 cell line","author":"Mohamadpour","year":"2016","journal-title":"Int. J. Health Stud."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117705_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1462-8902.2004.00350.x","article-title":"Glucosamine\u2010induced insulin resistance in L6 muscle cells","volume":"6","author":"Bailey","year":"2004","journal-title":"Diabetes Obes. Metabol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117705_bib46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0196-9781(99)00069-8","article-title":"Characterization of a functional AT1A angiotensin receptor in pancreatoma AR4\u20132J cells","volume":"20","author":"Cheung","year":"1999","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117705_bib47","first-page":"1090","article-title":"A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy","volume":"19","author":"Rahimi","year":"2014","journal-title":"J. Res. Med. Sci.: the official journal of Isfahan University of Medical Sciences"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117705_bib48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117705_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2016.06.008","article-title":"Quantifying ROS levels using CM-H2DCFDA and HyPer","volume":"109","author":"Oparka","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2025.117705_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0076-6879(95)60154-6","article-title":"[29] mitochondrial membrane potential monitored by JC-1 dye","volume":"260","author":"Reers","year":"1995","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib51","first-page":"15","article-title":"Use of a gastro-intestinal model and gastroplus\u2122 for the prediction of in vivo performance","volume":"6","author":"Naylor","year":"2006","journal-title":"J. Appl. Ther. Res."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117705_bib52","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1080\/17568919.2024.2400968","article-title":"Naphthoquinone fused diazepines targeting hyperamylasemia: potential therapeutic agents for diabetes and cancer","volume":"16","author":"Chahal","year":"2024","journal-title":"Future Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117705_bib53","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3409","article-title":"Amplex red assay for measuring hydrogen peroxide production from Caenorhabditis elegans","volume":"9","author":"Karakuzu","year":"2019","journal-title":"Bio-protocol"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117705_bib54","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1039\/D2MD00431C","article-title":"Development of thiazole-appended novel hydrazones as a new class of \u03b1-amylase inhibitors with anticancer assets: an in silico and in vitro approach","volume":"14","author":"Chahal","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117705_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107363","article-title":"Pyrano [2, 3-c] pyrazole fused spirooxindole-linked 1, 2, 3-triazoles as antioxidant agents: exploring their utility in the development of antidiabetic drugs via inhibition of \u03b1-amylase and DPP4 activity","volume":"147","author":"Chahal","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117705_bib56","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00216-009-3074-4","article-title":"Detection of angiotensin II type 1 receptor ligands by a cell-based assay","volume":"395","author":"Grie\u00dfner","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117705_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/abio.1996.0224","article-title":"A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to leu-enkephalin","volume":"237","author":"Carvalho","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2025.117705_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106660","article-title":"Electro-organic synthesis of C-5 sulfenylated amino uracils: optimization and exploring topoisomerase-I based anti-cancer profile","volume":"138","author":"Rani","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117705_bib59","doi-asserted-by":"crossref","first-page":"62","DOI":"10.6026\/97320630012062","article-title":"Molecular modeling and docking of small molecule inhibitors against NEK2","volume":"12","author":"Ramachandran","year":"2016","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2025.117705_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108114","article-title":"Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors","volume":"112","author":"Shaikh","year":"2022","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2025.117705_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43088-020-00059-7","article-title":"In silico molecular docking studies and MM\/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer","volume":"9","author":"Pattar","year":"2020","journal-title":"Beni-Suef University journal of basic and applied sciences"},{"issue":"28","key":"10.1016\/j.ejmech.2025.117705_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202301879","article-title":"Identification of azelastine and carvedilol as cholinesterase inhibitors via structure\u2010based virtual screening of FDA\u2010approved drugs","volume":"8","author":"Sharma","year":"2023","journal-title":"ChemistrySelect"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117705_bib63","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/092986611796378701","article-title":"Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar","volume":"18","author":"Liu","year":"2011","journal-title":"Protein Pept. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117705_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40360-023-00689-4","article-title":"In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus\u2122 software","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Pharmacology and Toxicology"},{"key":"10.1016\/j.ejmech.2025.117705_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1464-3456(05)80007-9","article-title":"IN vitro DMPK screening in drug discovery","volume":"6","author":"Chowdhury","year":"2005","journal-title":"Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS"},{"key":"10.1016\/j.ejmech.2025.117705_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114331","article-title":"LC-MS\/MS determination of guanabenz E\/Z isomers and its application to in vitro and in vivo DMPK profiling studies","volume":"205","author":"Xie","year":"2021","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.117705_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140466","article-title":"Synthesis, characterization, anxiolytic and anticonvulsant activity, DFT, molecular docking, DMPK studies of chalcone derived from maleic anhydride","volume":"1322","author":"Lucio","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.117705_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116465","article-title":"Antiviral drug discovery: pyrimidine entry inhibitors for Zika and dengue viruses","volume":"272","author":"Gallo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117705_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107039","article-title":"A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl) amino) ethyl) phenol, a promising adenosine derivative for glioblastoma treatment","author":"Murugesan","year":"2025","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117705_bib70","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bmc.2014.02.009","article-title":"Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus","volume":"22","author":"Park","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117705_bib71","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1021\/acsomega.3c07046","article-title":"Screening techniques for drug discovery in alzheimer's disease","volume":"9","author":"Maniam","year":"2024","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117705_bib72","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2174\/1389557511009011071","article-title":"Parallel artificial membrane permeability assay (PAMPA)-Is it better than Caco-2 for human passive permeability prediction?","volume":"10","author":"Reis","year":"2010","journal-title":"Mini Rev. Med. Chem."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2025.117772","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:55:58Z","timestamp":1772722558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":72,"alternative-id":["S0223523425004702"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117705","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of chromene-3-carboxylate derivatives as antidiabetic agents: Exploring the antidiabetic potential via dual inhibition of angiotensin II type 1 receptor and neprilysin enzyme","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117705"}}